XING Group seeks diagnostics JV partners; ready to release new COVID-19 test kit – CEO

BlueMount Capital client XING features in Mergermarket article

This article is from Unspecified for Health Care, Medical & Biotech

"XING Group Holdings, a Brisbane-based private Australian medical technology company, is actively seeking joint venture (JV) partners for a spin-off of its diagnostics division to facilitate product commercialization, starting with its COVID-19 test kit, said CEO Tom Esplin.

The company’s corporate advisor is BlueMount Capital (Queensland), but it welcomes approaches from other advisors with potential JV partners that can assist with manufacturing processes and have distribution capability, Esplin said.

XING Group plans to spin off its diagnostics division into a separate entity, in which it intends to maintain a majority stake with the rest owned by the JV partner, he said. It is already having partnership and investment conversations with diagnostics and life sciences companies in the US and Europe and is also willing to hear from significant players in other markets like China, Japan and South Korea, Esplin said."

Please download the full announcement via the link below.

For more information about XING / Project Curatio, please click here.

XING Group seeks diagnostics JV partners; ready to release new COVID-19 test kit – CEO

Related Attachments

April 20th, 2020

Mergermarket article: XING Group ( 108.18 KB )